key: cord-0826266-dn0ntwxs
authors: Gaunt, N.; Green, R.L.; Motta, L.F.; Jamieson, L.A.
title: Skin cancers in lockdown: no impact on pathological tumour staging
date: 2021-05-06
journal: Br J Dermatol
DOI: 10.1111/bjd.20438
sha: f83970aea4764e7521614be73e22d549a6be5bf1
doc_id: 826266
cord_uid: dn0ntwxs

The standard of care for suspected cancer referrals in the National Health Service (NHS) is two weeks from presentation to specialist review.(1) National hospital data has shown a 70.4% median reduction in Two Week Wait (TWW) referrals for suspected cancer as a direct result of the COVID‐19 pandemic and the national lockdown.(2) Colleagues from our institution reported a 56.4% reduction in TWW suspected skin cancer referrals in April 2020.(3) This trend is reflected in our dermatopathology workload data. The number of suspected cancer referrals began to climb steadily once restrictions were relaxed.(2) Our dermatopathology workload normalised in September 2020.

The standard of care for suspected cancer referrals in the National Health Service (NHS) is two weeks from presentation to specialist review. 1 National hospital data has shown a 70.4% median reduction in Two

Week Wait (TWW) referrals for suspected cancer as a direct result of the COVID-19 pandemic and the national lockdown. 2 Colleagues from our institution reported a 56.4% reduction in TWW suspected skin cancer referrals in April 2020. 3 This trend is reflected in our dermatopathology workload data. The number of suspected cancer referrals began to climb steadily once restrictions were relaxed. 2 Our dermatopathology workload normalised in September 2020.

In response to the COVID-19 pandemic, urgent guidance was issued by the British Association of Dermatologists and the British Society for Dermatological Surgery. It was recommended that clinicians should consider deferral of elective surgery for low risk cancers. 4

This retrospective cohort study aims to assess the impact of the United Kingdom national lockdown on the distribution of the pathological tumour stage (pT stage) (UICC TNM 8 th edition) and the proportion skin cancer cases with high-risk or poor prognostic pathological features in skin cancer excision specimens from our institution.

We obtained data from our laboratory reporting system at two time points: "pre-lockdown" (October -December 2019) and "post-lockdown" (October -December 2020), when the dermatopathology workload had normalised. We assessed all cases coded as "basal cell carcinoma (BCC)," "squamous cell carcinoma (SCC)" or "melanoma." We derived the pT stage and high-risk/adverse prognostic pathology data from Accepted Article excision specimens reported and staged according to guidelines issued by the Royal College of Pathologists. 5, 6, 7

For BCCs and SCCs, high risk pathological features included: high risk histological subtypes or growth patterns, poor differentiation, level of invasion beyond the subcutis, depth of invasion >6mm (BCC) or >4mm (SCC), perineural and lymphovascular invasion and pT stage 2, 3 or 4. 5, 6

For malignant melanoma, pathological features which have proven poor prognostic value included:

ulceration, mitotic rate ≥ 1 mitotic figure / mm 2 , perineural and lymphovascular invasion, satellite / microsatellite or in-transit metastases and vertical growth phase. 7

Clinical data regarding disease duration and/or duration from diagnosis to treatment was not obtained.

Our results and statistical methods are outlined in Table 1 Table 1) .

There was no statistically significant difference in the median thickness of BCCs, SCCs and melanomas.

(BCCs: p = 0.17; SCCs: p = 0.23 and malignant melanoma: p = 0.83) ( Table 1) . The limitations of this study include the generalisability its findings. All areas of the UK experienced significant reductions in suspected cancer referrals, however the rate of recovery has been variable. 2 This may be attributable to differences in access to healthcare and in health-seeking behaviours between regional cohorts.

This article is protected by copyright. All rights reserved It is known that most patients with non-melanoma skin cancers tend to delay their presentation. 8 The case numbers in the post-lockdown group are not significantly above what would normally be expected. The rebound predicted by our colleagues 3 does not appear to have happened at our centre within this study period. This post-lockdown group likely represents a sub-population of skin cancer patients. It remains to be seen whether there is another group of patients who are knowingly delaying their presentation to healthcare. Any future work should capture different regional cohorts and seek to clarify the duration and reasons for delay in presentation. https://www.rcpath.org/uploads/assets/fb177728-072d-4b8a-97ae94319eaac5fd/Dataset-for-thehistological-reporting-of-primary-cutaneous-malignant-melanoma-and-regional-lymph-nodes.pdf Funding sources: none.

Conflicts of interest: none to declare.

This article is protected by copyright. All rights reserved Table 1 

National Institute for Health and Care Excellence

Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study